Comparison

Pramlintid vs. Retatrutide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Pramlintid

Pramlintide mimics the beta-cell hormone amylin, which is co-secreted with insulin. It slows gastric emptying, suppresses postprandial glucagon release and promotes satiety — thereby blunting post-meal blood-glucose spikes.

Retatrutide

Retatrutide is a 39-amino-acid peptide with agonism at three incretin/energy-balance receptors: GLP-1R (insulin secretion, satiety), GIPR (insulin sensitivity, lipid metabolism) and the glucagon receptor (energy expenditure, lipolysis). The added glucagon activation is intended to raise catabolic energy expenditure while concurrent GLP-1/GIP action compensates the hyperglycaemic effect. Albumin binding via a fatty-acid side chain enables weekly dosing.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Pramlintid	Retatrutide
Germany	Unapproved	Unapproved
JP	—	Unapproved
United States	Prescription	Unapproved

Full entries

Frequently asked questions

What is the difference between Pramlintid and Retatrutide?: Pramlintid is classified as "Metabolic", while Retatrutide is classified as "Metabolic". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Pramlintid or Retatrutide?: The highest available evidence level is "Human RCT" for Pramlintid and "Human RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Pramlintid and Retatrutide in Germany and the United States?: Germany: Pramlintid — Unapproved, Retatrutide — Unapproved. United States: Pramlintid — Prescription, Retatrutide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Pramlintid

Retatrutide

Germany

Unapproved

—

Unapproved

United States

Prescription

Unapproved

Frequently asked questions

What is the difference between Pramlintid and Retatrutide?

Pramlintid is classified as "Metabolic", while Retatrutide is classified as "Metabolic". Pramlintid: Pramlintide is a synthetic analog of the hormone amylin. It is used as an adjunct to mealtime insulin therapy in type 1 and type 2 diabetes and, among other things, slows gastric emptying. Retatrutide: Synthetic triagonist peptide that simultaneously activates the GLP-1, GIP and glucagon receptors. Developed by Eli Lilly; in phase-3 trials for obesity (TRIUMPH programme) and type 2 diabetes. No marketing approval yet. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Pramlintid or Retatrutide?

The highest available evidence level is "Human RCT" for Pramlintid and "Human RCT" for Retatrutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Pramlintid and Retatrutide in Germany and the United States?

Germany: Pramlintid — Unapproved, Retatrutide — Unapproved. United States: Pramlintid — Prescription, Retatrutide — Unapproved. These are factual summaries with source and review date on the individual pages.